Nancy S Green
Affiliation: Columbia University
- Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital useNancy S Green
Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, Columbia University Medical Center, New York, New York
Pediatr Blood Cancer 63:2146-2153. 2016..Large deviation from historical personal best (PBest) HbF, a clinic-based version of maximum dose, may identify a subset with suboptimal HU adherence over time...
- Enhanced Long-Term Brain MRI Evaluation of Children with Sickle Cell Disease Following Hematopoietic Cell TransplantationNancy S Green
Departments of Pediatrics, Columbia University Medical Center, NY Electronic address
Biol Blood Marrow Transplant . 2017..While confirmation in larger prospective studies and evaluation by neurocognitive testing are needed, these findings suggest that WMH is a useful biomarker of neurovasculopathy post-transplant for SCD...
- Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyureaNancy S Green
Department of Pediatrics, Columbia University, New York, New York, USA
PLoS ONE 8:e55709. 2013..The sole approved pharmacologic therapy for this disease is hydroxyurea, with effects largely attributable to induction of fetal hemoglobin...
- Genetic modifiers of HbF and response to hydroxyurea in sickle cell diseaseNancy S Green
Department of Pediatrics, Columbia University Medical Center, New York, New York 10032, USA
Pediatr Blood Cancer 56:177-81. 2011..We review these methods and findings, and speculate on applying pharmaco-genetics to optimize hydroxyurea therapy aimed at increasing HbF...
- Fetal hemoglobin levels in African American and Hispanic children with sickle cell disease at baseline and in response to hydroxyureaKatherine L Ender
Pediatric Hematology, Columbia University Medical Center, NY 10032, USA
J Pediatr Hematol Oncol 33:496-9. 2011..If generalizable, our results support combining these 2 groups in future clinical and translational analyses focused on HbF and response to HU in this ethnically mixed patient population...
- Parental and other factors associated with hydroxyurea use for pediatric sickle cell diseaseSuzette O Oyeku
Department of Pediatrics, Division of General Pediatrics, Children s Hospital at Montefiore, Albert Einstein College of Medicine of Yeshiva University, Bronx, New York 10467, USA
Pediatr Blood Cancer 60:653-8. 2013..Hydroxyurea (HU) is highly effective treatment for sickle cell disease (SCD). While pediatric use of HU is accepted clinical practice, barriers to use may impede its potential benefit...
- Incomplete follow-up of hemoglobinopathy carriers identified by newborn screening despite reporting in electronic medical recordsMara Burney
School of Nursing, Columbia University Medical Center, New York, New York 10032, USA
J Natl Med Assoc 103:852-6. 2011..Has the recent availability of newborn hemoglobinopathy screening results within patient electronic medical records (EMR) of birth hospitals facilitated follow-up by primary care pediatric providers?..
- Do difficulties in swallowing medication impede the use of hydroxyurea in children?ElShadey Bekele
Department of Pediatrics, Columbia University Medical Center, New York, New York
Pediatr Blood Cancer 61:1536-9. 2014..Use of hydroxyurea (HU) in children with sickle cell disease (SCD) may be hampered by its formulation as a capsule and the limited availability of liquid HU...
- Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell diseaseArlene Smaldone
Columbia University School of Nursing, New York, NY, United States College of Dental Medicine, Columbia University Medical Center, New York, NY, United States
Contemp Clin Trials 49:134-42. 2016..This paper presents the rationale, study design and protocol for an open label randomized controlled trial to improve parent-youth partnerships in self-management and medication adherence to HU in adolescents with SCD...
- Mortality of New York children with sickle cell disease identified through newborn screeningYing Wang
1 School of Public Health, University at Albany, State University of New York, Albany, New York, USA 2 Division of Data Management and Research, Office of Primary Care and Health Management System, New York State Department of Health, Albany, New York, USA
Genet Med 17:452-9. 2015..We sought to estimate childhood sickle cell disease mortality and risk factors among a statewide birth cohort with sickle cell disease identified through newborn screening...
- Emerging science of hydroxyurea therapy for pediatric sickle cell diseaseNancy S Green
Division of Pediatric Hematology Oncology Stem Cell Transplantation, Department of Pediatrics, Columbia University, New York, New York
Pediatr Res 75:196-204. 2014..Understanding the genetic and other factors underlying the variability in therapeutic effects of HU for pediatric SCD is critical for prospectively predicting good responders and for designing other effective therapies. ..
- A framework for key considerations regarding point-of-care screening of newbornsAlex R Kemper
Department of Pediatrics, Duke University, Durham, North Carolina, USA
Genet Med 14:951-4. 2012....
- Awareness of sickle cell among people of reproductive age: Dominicans and African Americans in northern ManhattanSaira Siddiqui
Department of Pediatrics, Columbia University, 622 W 168th St, Rm VC4 412, New York, NY 10032, USA
J Urban Health 89:53-8. 2012..Y.C. community affected by sickle conditions frequently lack basic relevant information, with larger information gaps among Dominicans. Expanded efforts are warranted to inform young adults of diverse affected communities...